Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,623.11 +1,975.30 (+3.20%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
GSK Jan 2025 50.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 02:38PM EDT
| Previous close | 0.7500 |
| Open | 0.6700 |
| Bid | 0.6000 |
| Ask | 0.8000 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.6700 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 766 |
Simply Wall St.GSK First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GSK ( LON:GSK ) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q 2023). Net income...
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
PA Media: MoneyGSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
© 2024 Yahoo. All rights reserved.